Sydnexis Announces UK Approval of Ryjunea® by Partner Santen to Slow Progression of Childhood Myopia

DEL MAR, Calif.–( BUSINESS WIRE )–Sydnexis, Inc., a biopharmaceutical company focused on pediatric progressive myopia (PPM), today noted its partner Santen’s announcement that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Ryjunea ® (low-dose atropine 0.1 mg/ml), the first MHRA approved treatment in the UK to slow the progression of myopia in children aged 3-14 years with a progression rate of 0.5 D or more per year and a severity of -0.5 D to -6.0 D. This approval comes after authorization by the European Commission and the initial launch in Germany earlier this year. Sydnexis’ low-dose atropine eye drop SYD-101 is licensed to Santen in Europe, the Middle East, and Africa, which Santen commercializes under the brand name Ryjunea®. Santen is a global pharmaceutical company with over 135 years of experience dedicated to advancing eye health and improving lives through better vision. “We are thrilled that the MHRA has granted approval of Ryjunea ® to Santen, marking another important milestone in bringing this innovative therapy to even more patients in need,” said Perry Sternberg, Chief Executive Officer of Sydnexis. “Backed by the global STAR study, this announcement underscores the potential of an approved low-dose atropine solution to address a significant unmet medical need for children with progressive myopia worldwide.” About Sydnexis, Inc . Sydnexis, Inc . is a biopharmaceutical company dedicated to advancing care for pediatric progressive myopia. The company’s lead compound, SYD-101, is currently approved in the European Union, where it is licensed to Santen S.A. and marketed as Ryjunea ® . Sydnexis is supported by leading life-science investors, including Visionary Ventures, RA Capital, Longitude Capital, and Bluestem Capital. For more information on Sydnexis, please visit www.sydnexis.com . Contacts For media inquiries, please contact: F TI Consulting Robert Stanislaro or Helen O’Gorman [email protected] We respect your privacy By clicking “Accept” or continuing to use this website, you consent to the use of cookies, tags, pixels, and similar technologies set by us and our third-party partners. We use these tools to personalize your experience, for marketing, and for analytics. You may block some of these by clicking “Reject” or by visiting the preference center (click “Customize”). By using this site you agree to our Privacy Policy and Terms and Conditions . Functional Functional Always active The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network. Preferences Preferences The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user. Statistics Statistics The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you. Marketing Marketing The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes. Manage options Manage services Manage {vendor_count} vendors Read more about these purposes Accept Reject Customize Save preferences Customize {title} {title} {title}

The release as fetched from its publisher. sydnexis.com ↗